Jacquelyn Dosal, MD
Dermatology · Coral Gables, FLNPI 1114159837
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boehringer Ingelheim at 49.8% of the total. Reporting peaked in 2024 at $5,021 and has fallen 93.8% since, to $312 in 2025.
Across 215 payments — averaging $41.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$4K
- AbbVie$1K
- Revance Therapeutics, Inc.$938
- Regeneron Healthcare Solutions, Inc.$275
- Galderma Laboratories, L.p.$274
- E.r. Squibb & Sons, L.L.C.$186
- plus $2K from 25 others
What the payments were for
- Consulting fees$2,50028%
- Speaking & faculty fees$1,91421%
- Food & beverage$4,51950%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $4,462 |
| AbbVie(2 entities) | 84 | $1,297 |
| Revance Therapeutics, Inc. | 13 | $938 |
| Regeneron Healthcare Solutions, Inc. | 13 | $275 |
| Galderma Laboratories, L.p. | 11 | $274 |
| E.r. Squibb & Sons, L.L.C. | 7 | $186 |
| Sun Pharmaceutical Industries Inc. | 7 | $155 |
| Pfizer | 8 | $145 |
| Dermira, Inc. | 7 | $136 |
| Almirall LLC | 5 | $102 |
| Sanofi | 5 | $98 |
| Incyte Corporation | 6 | $98 |
| Arcutis Biotherapeutics, Inc. | 5 | $97 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $87 |
| Merz North America, Inc. | 3 | $77 |
| VYNE Pharmaceuticals Inc. | 3 | $75 |
| Johnson & Johnson | 3 | $56 |
| Lilly USA, LLC | 3 | $54 |
| UCB, Inc. | 3 | $45 |
| EPI Health, LLC | 2 | $43 |
| Journey Medical Corporation | 4 | $35 |
| Amgen | 1 | $32 |
| Biofrontera Inc. | 2 | $31 |
| Bristol Myers Squibb | 1 | $27 |
| Novartis | 1 | $25 |
| Strata Skin Sciences, Inc. | 2 | $24 |
| Covidien LP | 1 | $22 |
| Promius Pharma LLC | 1 | $20 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $20 |
| Aclaris Therapeutics, Inc. | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,967 in reported general payments places this provider in the 75th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $45,876 |
| Mupirocin | 13 | $335 |
| Ketoconazole | 20 | $266 |
| Doxycycline Hyclate | 12 | $177 |
| Triamcinolone Acetonide | 14 | $110 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Coral Gables
- Jeremy GreenCoral Gables$952K
- Javier Alonso-LlamazaresCoral Gables$854K
- Joely Kaufman-JanetteCoral Gables$242K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.